EP4164626A4 - Combination antibacterial composition and method for antibacterial therapy - Google Patents
Combination antibacterial composition and method for antibacterial therapyInfo
- Publication number
- EP4164626A4 EP4164626A4 EP21825333.4A EP21825333A EP4164626A4 EP 4164626 A4 EP4164626 A4 EP 4164626A4 EP 21825333 A EP21825333 A EP 21825333A EP 4164626 A4 EP4164626 A4 EP 4164626A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibacterial
- combination
- therapy
- composition
- antibacterial composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title 2
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202041025097 | 2020-06-15 | ||
PCT/US2021/037245 WO2021257461A1 (en) | 2020-06-15 | 2021-06-14 | Combination antibacterial composition and method for antibacterial therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4164626A1 EP4164626A1 (en) | 2023-04-19 |
EP4164626A4 true EP4164626A4 (en) | 2024-07-03 |
Family
ID=79268317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21825333.4A Pending EP4164626A4 (en) | 2020-06-15 | 2021-06-14 | Combination antibacterial composition and method for antibacterial therapy |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4164626A4 (en) |
WO (1) | WO2021257461A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005020998A1 (en) * | 2003-09-03 | 2005-03-10 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of moxifloxacin and processes for their preparation |
US20110190199A1 (en) * | 2008-09-03 | 2011-08-04 | Pfizer Inc. | Combination Therapy for Tuberculosis |
WO2016120258A1 (en) * | 2015-01-27 | 2016-08-04 | Janssen Pharmaceutica Nv | Dispersible compositions |
US20180280401A1 (en) * | 2015-10-14 | 2018-10-04 | The Global Alliance For Tb Drug Development, Inc. | Combination antibacterial composition and short-course antibacterial regimen |
WO2021016012A1 (en) * | 2019-07-19 | 2021-01-28 | The Global Alliance For Tb Drug Development, Inc. | Pretomanid compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3906365A1 (en) * | 1988-07-15 | 1990-01-18 | Bayer Ag | 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM |
WO2014016850A1 (en) * | 2012-07-24 | 2014-01-30 | Mylan Laboratories Limited | Stable pharmaceutical composition of fluindione |
WO2016116892A1 (en) * | 2015-01-24 | 2016-07-28 | Wockhardt Limited | Antibacterial compositions |
-
2021
- 2021-06-14 EP EP21825333.4A patent/EP4164626A4/en active Pending
- 2021-06-14 WO PCT/US2021/037245 patent/WO2021257461A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005020998A1 (en) * | 2003-09-03 | 2005-03-10 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of moxifloxacin and processes for their preparation |
US20110190199A1 (en) * | 2008-09-03 | 2011-08-04 | Pfizer Inc. | Combination Therapy for Tuberculosis |
WO2016120258A1 (en) * | 2015-01-27 | 2016-08-04 | Janssen Pharmaceutica Nv | Dispersible compositions |
US20180280401A1 (en) * | 2015-10-14 | 2018-10-04 | The Global Alliance For Tb Drug Development, Inc. | Combination antibacterial composition and short-course antibacterial regimen |
WO2021016012A1 (en) * | 2019-07-19 | 2021-01-28 | The Global Alliance For Tb Drug Development, Inc. | Pretomanid compositions |
Non-Patent Citations (1)
Title |
---|
See also references of WO2021257461A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021257461A1 (en) | 2021-12-23 |
EP4164626A1 (en) | 2023-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279748A (en) | Composition and method for treating pain | |
IL285886A (en) | Compositions and methods for treating laminopathies | |
GB202011871D0 (en) | Composition and method | |
IL277315B (en) | Methods and composition for treating coronavirus infection | |
IL285796A (en) | Methods and compositions for treating | |
EP4181928A4 (en) | Compositions and methods for treating lung inflammation | |
GB202100998D0 (en) | Composition and method | |
GB202100997D0 (en) | Composition and method | |
GB2593010B (en) | Composition and Method | |
EP4164626A4 (en) | Combination antibacterial composition and method for antibacterial therapy | |
EP4164645A4 (en) | Combination antibacterial composition and method for antibacterial therapy | |
GB202102310D0 (en) | Composition and method | |
GB202016644D0 (en) | Composition and method | |
EP3946302A4 (en) | Methods and compositions for treating pain | |
GB2603642B (en) | Method and composition | |
EP4142687C0 (en) | Composition for treating and/or preventing vestibulodynia | |
EP4175627A4 (en) | Composition and method for treating infections | |
GB2598715B (en) | Composition and method | |
EP4069701A4 (en) | Composition and method for treating cancer | |
GB202218059D0 (en) | Treatment composition | |
GB202113085D0 (en) | Composition and method | |
GB202113086D0 (en) | Composition and method | |
GB202109827D0 (en) | Method and composition | |
GB202108601D0 (en) | Composition and method | |
GB202105673D0 (en) | Method and composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230111 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240603 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/20 20060101ALI20240528BHEP Ipc: A61P 17/02 20060101ALI20240528BHEP Ipc: A61K 31/7036 20060101ALI20240528BHEP Ipc: A61K 31/20 20060101AFI20240528BHEP |